| Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life J Guedj, H Dahari, L Rong, ND Sansone, RE Nettles, SJ Cotler, ... Proceedings of the National Academy of Sciences 110 (10), 3991-3996, 2013 | 284 | 2013 |
| Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea D Sissoko, C Laouenan, E Folkesson, AB M’lebing, AH Beavogui, S Baize, ... PLoS medicine 13 (3), e1001967, 2016 | 219 | 2016 |
| Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate RM Ribeiro, H Li, S Wang, MB Stoddard, GH Learn, BT Korber, ... PLoS pathogens 8 (8), e1002881, 2012 | 131 | 2012 |
| Second‐phase hepatitis C virus RNA decline during telaprevir‐based therapy increases with drug effectiveness: implications for treatment duration J Guedj, AS Perelson Hepatology 53 (6), 1801-1808, 2011 | 120 | 2011 |
| A perspective on modelling hepatitis C virus infection J Guedj, L Rong, H Dahari, AS Perelson Journal of viral hepatitis 17 (12), 825-833, 2010 | 94 | 2010 |
| Maximum likelihood estimation in dynamical models of HIV J Guedj, R Thiébaut, D Commenges Biometrics 63 (4), 1198-1206, 2007 | 92 | 2007 |
| Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model L Rong, J Guedj, H Dahari, DJ Coffield Jr, M Levi, P Smith, AS Perelson PLoS computational biology 9 (3), e1002959, 2013 | 76 | 2013 |
| Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics J Guedj, AU Neumann Journal of theoretical biology 267 (3), 330-340, 2010 | 67 | 2010 |
| Dominance of the CD4+ T helper cell response during acute resolving hepatitis A virus infection Y Zhou, B Callendret, D Xu, KM Brasky, Z Feng, LL Hensley, J Guedj, ... Journal of Experimental Medicine 209 (8), 1481-1492, 2012 | 66 | 2012 |
| Mathematical modeling of HCV infection: what can it teach us in the era of direct antiviral agents? A Chatterjee, J Guedj, AS Perelson Antiviral therapy 17 (6 0 0), 1171, 2012 | 63 | 2012 |
| Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection DTY Lau, A Negash, J Chen, N Crochet, M Sinha, Y Zhang, J Guedj, ... Gastroenterology 144 (2), 402-413. e12, 2013 | 61 | 2013 |
| Practical identifiability of HIV dynamics models J Guedj, R Thiébaut, D Commenges Bulletin of mathematical biology 69 (8), 2493-2513, 2007 | 61 | 2007 |
| Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C Y Rotman, M Noureddin, JJ Feld, J Guedj, M Witthaus, H Han, YJ Park, ... Gut 63 (1), 161-169, 2014 | 58 | 2014 |
| Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study D Sissoko, S Duraffour, R Kerber, JS Kolie, AH Beavogui, AM Camara, ... The Lancet Global Health 5 (1), e80-e88, 2017 | 54 | 2017 |
| Dose regimen of favipiravir for Ebola virus disease F Mentré, AM Taburet, J Guedj, X Anglaret, S Keïta, X de Lamballerie, ... The Lancet Infectious Diseases 15 (2), 150-151, 2015 | 53 | 2015 |
| Understanding silibinin’s modes of action against HCV using viral kinetic modeling J Guedj, H Dahari, RT Pohl, P Ferenci, AS Perelson Journal of hepatology 56 (5), 1019-1024, 2012 | 53 | 2012 |
| Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128) J Guedj, H Dahari, E Shudo, P Smith, AS Perelson Hepatology 55 (4), 1030-1037, 2012 | 53 | 2012 |
| Modelling hepatitis C therapy—predicting effects of treatment AS Perelson, J Guedj Nature reviews Gastroenterology & hepatology 12 (8), 437, 2015 | 51 | 2015 |
| Hepatitis C viral kinetics in the era of direct acting antiviral agents and interleukin-28B H Dahari, J Guedj, AS Perelson, TJ Layden Current hepatitis reports 10 (3), 214-227, 2011 | 49 | 2011 |
| Estimating a difference of Kullback–Leibler risks using a normalized difference of AIC D Commenges, A Sayyareh, L Letenneur, J Guedj, A Bar-Hen The Annals of Applied Statistics 2 (3), 1123-1142, 2008 | 49 | 2008 |
Alan S PerelsonSenior Fellow, Los Alamos National LaboratoryVerified email at lanl.gov
